IRLAB Therapeutics
13.25
SEK
+4.33 %
IRLAB A
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
+4.33%
+6%
-13.11%
-15.06%
+76.67%
+96.59%
-73.92%
-58.51%
+14.27%
irlab.se/investor-relations
IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.
Revenue
5.68M
EBIT %
-3,182.57 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
IRLAB A
Daily low / high price
12.65 / 13.5
SEK
Market cap
687.26M SEK
Turnover
206.18K SEK
Volume
16K
Latest videos
Financial calendar
Annual report
2025-02-12
Interim report
2025-05-07
General meeting
2025-05-21
Interim report
2025-07-09
Interim report
2025-10-29
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 9.3 % | 9.3 % |
| Daniel Johnsson | 8.7 % | 8.7 % |
| Ancoria Insurance Public | 7.4 % | 7.4 % |
| FV Group AB | 7.1 % | 7.1 % |
| Fjärde AP-fonden | 6.7 % | 6.7 % |
| Unionen | 3.9 % | 3.9 % |
| Nordnet Pensionsförsäkring AB | 3.7 % | 3.7 % |
| Philip Diklev | 2.9 % | 2.9 % |
| Marinvest Holding AB | 2.3 % | 2.3 % |
| Hans Victor | 2.0 % | 2.0 % |
ShowingAll content types
IRLAB to Present at BioStock Life Science Summit 2024
Redeye: IRLAB Q3 2024 - Several catalysts ahead
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools